S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Behavioral Profiling as a Strategy to Stem Weight-Loss Drug Discontinuation

While clinical trials demonstrate sustained weight loss of 15–22% over 72 weeks, real-world data reveals that up to 67% of patients discontinue GLP-1 and GIP medications within the first year. This gap highlights a critical shift in focus from purely biological outcomes to the psychological drivers of treatment adherence.

Behavioral Profiling as a Strategy to Stem Weight-Loss Drug Discontinuation
Photo: Bio & News

The upcoming Xtalks webinar on October 29, 2026, aims to address this attrition by examining the intersection of biometric data and patient psychology. Experts from Clinical ink—including Christian Djurhuus, MD, PhD, and Nicholas Alp, MD, PhD—will present findings from a study of 1,056 U.S. adults. The research utilizes the SPUR behavioral framework to categorize patients based on treatment identity, confidence, and internal motivations, rather than relying solely on clinical metrics.

By integrating biometrics with sociometrics and psychometrics, the speakers argue that pharma professionals can identify adherence risks before patients abandon their regimens. The session will introduce Kaitality, a wellness platform designed to synthesize these data points into personalized support programs. This approach seeks to move beyond the common hurdles of cost and side effects, focusing instead on the underlying beliefs that dictate long-term engagement with obesity therapies.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!